Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate with clinically progressive stage IVA or IVB disease after at least primary androgen ablation with either orchiectomy or LHRH agonist and only one cytotoxic chemotherapy regimen
• Measurable disease with a maximum of 10 measurable lesions OR nonmeasurable disease
• Serum testosterone no greater than 50 ng/mL if no prior bilateral orchiectomy
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• ECOG 0 or 1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3 (transfusion independent)
• No disseminated intravascular coagulation
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 3 times ULN
• Renal:
• Creatinine no greater than 1.5 times ULN
• Other:
• Fertile patients must use effective contraception
• No currently active second malignancy other than nonmelanoma skin cancers
• No active infection
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy and recovered
• Chemotherapy:
• See Disease Characteristics
• At least 6 weeks since prior suramin
• At least 4 weeks since other prior chemotherapy
• No prior therapy with camptothecin or any of its analogues
• Endocrine therapy:
• Prior second line hormonal therapy allowed
• At least 4 weeks since prior hormonal therapy
• Concurrent treatment with LHRH agonists allowed and required for
• patients without orchiectomy
• No concurrent hormonal therapy except for nondisease related conditions
• Concurrent corticosteroids allowed if on stable dose for at least 6 weeks
• before study
• No concurrent dexamethasone as an antiemetic
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• No palliative radiotherapy
• At least 8 weeks since prior strontium 89 or samarium 153
• Surgery:
• At least 3 weeks since major surgery and recovered